patients, respectively. Overall, 60% of patients had a platinum-free interval of >12 months before randomization and 45.8% of patients finished COMPASS trial as per protocol. The main reasons for withdrawal were progression under treatment (18.6%), toxicity (15.3%), death (13.6%) and patient wish (6.8%). Post-protocol maintenance therapy was given to 23.8% of patients. No differences in patient characteristics were observed. Conclusion Based on this data no significant signal for a non-inferiority of the study arms have been observed. Study is ongoing and open for recruitment.

**2022-RA-676-ESGO**

**UTILIZATION OF LIGASURE MARYLAND JAW OPEN SEALER/DIVIDER WITH NANOCOATING IMPROVES PERIOPERATIVE PARAMETERS IN WOMEN WITH ADVANCED OVARIAN CANCER SUBJECTED TO CYTOREDUCTIVE SURGERY**

Dimitrios Tsolakidis, Kimon Chatzistamatiou, Dimitris Zouzoulas, Efthalia Markopoulou, Stavros Miypsichiotis, Elieni Mipi, Themistoklis Mikos, George Pados, Grigorios Grimbizis. 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki; Greece

10.1136/ijgc-2022-ESGO.542

Introduction/Background Cytoreductive surgery is a pivotal treatment for women with advanced ovarian cancer. Optimal cytoreduction aims to achieve no visible tumor or residual disease less than 1 cm. This surgical procedure often has high morbidity due to the surgical complexity. The objective of the presented analysis is to identify whether using the Ligasure® Maryland-jaw open sealer/divider (LMjsd) with nanocoating facilitates cytoreductive surgery by reducing intraoperative bleeding and therefore other parameters regarding hospitalization.

Methodology Women with stage III/IV ovarian cancer who were referred to the Department of Gynaecologic Oncology, 1st Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Thessaloniki, Greece, and were subjected to primary/interval cytoreductive surgery were retrospectively allocated into two distinct groups, depending on whether the LMjsd was used or not. The comparison focused on differences between the two groups regarding intraoperative blood loss and blood transfusion, duration of surgery, blood transfusion within the post-operative course, Intensive Care Unit (ICU) and overall hospital length of stay.

Results Between January 2012 and April 2022, 306 ovarian cancer patients were surgically treated; of these, 230 were stage III/IV. In the group of women (N=56), who were operated on using the LMjsd, duration of surgery (p<0.001) was increased, but blood loss (p=0.001) during surgery was significantly decreased compared to cases treated without the LMjsd (N=174). The intra-operative blood transfusion rate, but not the amount of transfused packed red blood cells (p=0.752), was significantly decreased in the first group (p=0.032), whereas post-operative blood transfusion rate was not affected (p=0.063). Moreover, ICU and overall hospital length of stay were significantly decreased in cases where the LMjsd was used (p<0.001 for both parameters).

Conclusion The LMjsd is associated to less intra-operative bleeding and transfusion rates; ICU and overall hospital length of stay is improved in women subjected to cytoreductive surgery for advanced ovarian cancer.

**2022-RA-680-ESGO**

**SAFETY AND EFFICACY OF MORAB-202 IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RESULTS FROM THE EXPANSION PART OF A PHASE 1 TRIAL IN JAPAN**

Shin Nishio, 1Mayu Yurukawa, 2Koji Matsumoto, 2Kazuhiko Takehama, 3Kosai Hasegawa, 4Yasuuki Hirashima, 4Hidemori Kato, 4Hiruki Ikawa, 4Maiko Nomoto, 5Seichi Hayato, 6Yohai Otake, 7Takuma Miura, 8Kan Yonemori. 1Kurume University School of Medicine, Fukuoka, Japan; 2Cancer Institute Hospital, Tokyo, Japan; 3Hyogo Cancer Center, Hyogo, Japan; 4National Hospital Organization Shikoku Cancer Center, Ehime, Japan; 5Saitama Medical University International Medical Center, Saitama, Japan; 6Shuzoku Cancer Center, Shizuoka, Japan; 7Hokkaido Cancer Center, Sapporo, Japan; 8Eisai Co. Ltd., Tokyo, Japan; 9National Cancer Center Hospital, Tokyo, Japan

10.1136/ijgc-2022-ESGO.543

Introduction/Background MORAB-202 is an antibody-drug conjugate consisting of farletuzumab (an antibody targeting folate-receptor alpha [FRα]) and eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin-B-cleavable linker. Antitumour activity was observed in the dose-escalation part of this phase 1 study; MORAB-202 0.9 mg/kg and 1.2 mg/kg Q3W were chosen for the expansion part of this study in patients with platinum-resistant ovarian cancer (PROC).

Methodology The primary objective for the expansion part of this phase 1 study was to define the safety and tolerability of MORAB-202. Secondary objectives included pharmacokinetic characterization and efficacy assessment (best overall response, ORR, PFS, and OS). Eligible patients had measurable disease per RECIST v1.1 and had ≤2 chemotherapy regimens after PROC diagnosis. The expansion phase began at the 0.9 mg/kg dose (Cohort 1); Cohort 2 (1.2 mg/kg) was initiated after a Cohort 1 safety assessment. Tumour responses were assessed per RECIST v1.1 by investigator.

**Abstract 2022-RA-680-ESGO Table 1**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Cohort 1</th>
<th>Cohort 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR (%)</td>
<td>1 (4.2)</td>
<td>0</td>
</tr>
<tr>
<td>PR (%)</td>
<td>5 (20.8)</td>
<td>11 (52.4)</td>
</tr>
<tr>
<td>SD (%)</td>
<td>10 (41.7)</td>
<td>9 (42.9)</td>
</tr>
<tr>
<td>PD (%)</td>
<td>8 (33.3)</td>
<td>1 (4.8)</td>
</tr>
<tr>
<td>ORR (%)</td>
<td>6 (25.0)</td>
<td>11 (52.4)</td>
</tr>
<tr>
<td>DCR (%)</td>
<td>16 (66.7)</td>
<td>20 (95.2)</td>
</tr>
<tr>
<td>Median PFS, mos (95% CI)*</td>
<td>6.7 (1.5-12.0)</td>
<td>8.2 (4.2-10.6)</td>
</tr>
</tbody>
</table>

*CI calculations: ORR, DCR—Clopper-Pearson’s exact method; PFS, OS—Explan-Meier estimate and Greenwood Formula.

**Results** Twenty-four patients were treated in Cohort 1; 21 patients were treated in Cohort 2. Grade ≥3 TEAEs occurred...
in 33.3% of patients in Cohort 1; 28.6% of patients in Cohort 2. The most common TEAE was interstitial lung disease (ILD)/pneumonitis at both dose levels (Cohort 1: 37.5% [n=9; 8 with grade 1, 1 with grade 2]; Cohort 2: 66.7% [n=14; 6 with grade 1, 7 with grade 2, 1 with grade 3]). Other common TEAEs of any grade are in table 1. ORRs were 25.0% and 52.4% in Cohorts 1 and 2, respectively (table 1). Antitumour activity was observed across FRα-expression levels (<50% and ≥50%) and will be presented.

Conclusion In the PROC population, antitumour activity was seen with MORAb-202 0.9 mg/kg and 1.2 mg/kg dosages. Despite small patient numbers, efficacy was observed irrespective of FRα-expression levels. ILD/pneumonitis (mostly low-grade) was the most common TEAE.

**WHAT IS BEYOND BRCA MUTATIONAL STATUS IN HIGH GRADE SEROUS OVARIAN CANCER? THE ROLE OF HORMONE RECEPTORS EXPRESSION**

Emanuele Perrone, Riccardo Tudisco, Fià Clara Pafundi, Davide Guido, Alessandra Ciucci, Enrica Martelli, Gian Franco Zannoni, Alessia Piermatti, Claudia Marchetti, Camilla Nero, Daniela Gallo, Giovanni Scambia, Anna Fagotti.

1Gynecologic Oncology Unit, Dipartimento per le Scienze della Salute della Donna del Bambino e di Sa, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2Dipartimento per le Scienze della Salute della Donna del Bambino e di Sa, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
3Unit of Translational Medicine for Woman and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
4Gynecopathology and Breast Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Introduction/Background Several studies have explored the prognostic role of hormone receptor expression in high grade serous ovarian cancer (HGSOC). However, few reports have investigated their expression according to BRCA mutational status. Notably, there is evidence of a strong interaction between BRCA1/2 proteins and steroid hormones system, including higher titres of estradiol and progesterone in BRCA1/2 mutation carriers. Thus, we sought to explore the hormone receptor pattern and its potential prognostic impact in a well-characterized cohort of HGSOC patients stratified for BRCA status.

Methodology We assessed ERα, ERβ1, ERβ2, ERβ5, PR (progesterone receptor) and AR (androgen receptor) expression by immunohistochemistry in a single-centre observational retrospective cohort study of 207 HGSOC women, profiled for BRCA1/2 mutation status with available clinical and molecular features.

Results 135 BRCA-wild type (BRCA-wt) and 72 BRCA1/2 mutation carriers (BRCA-mut) were observed. No significant differences were detected in hormone receptor expression between the two populations. However, in the subgroup analysis according to menopausal status, a significantly lower ERα expression was found in pre-menopausal BRCA-mut compared to BRCA-wt patients (p=0.02) (figure 1). Regarding survival analysis, none of the examined hormone receptors had a significant prognostic role. However, a higher ERα/ERβ5 nuclear ratio differently affected outcome according to BRCA status: positively in BRCA-wt cohort (HR 0.77; CI 0.61–0.96; p=0.019) and negatively in BRCA-mut cohort (HR 1.41; CI 1.06–1.87; p=0.020) (table 1). Finally, higher PR levels were associated with platinum sensitivity in the whole population (p=0.019).

**PARADIGM SHIFT IN SURGICAL APPROACH IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER IN THE UNIVERSITY HOSPITALS OF LEICESTER**

Anas Barakat, Aamn Ismail, Supratik Chattopadhyay.

1Gynaecology Oncology Department, University Hospitals of Leicester NHS Trust, LEICESTER, UK
2Leicester Cancer Research Centre, University of Leicester, Leicester, UK

Introduction/Background Surgery for advanced ovarian cancer (AOC) has evolved over the past decade to ingeminate the...